Site Search
Professionals 111 results
Capabilities 48 results
Industry
Winston’s financial crimes compliance lawyers have been providing regulatory compliance counseling and enforcement services related to the Bank Secrecy Act (BSA), the Anti-Money Laundering Act of 2020 (AML), and countering the financing of terrorism (CFT) policy for decades. We also have experience with international AML matters, including in the EU and with respect to Financial Actions Task Force (FATF) recommendations.
Practice Area
Practice Area
International trade is essential for the growth and development of global economies and businesses. As international trade has expanded and developed, so too have the myriad rules and regulations that govern it. The global compliance environment is becoming more complex by the day and can be difficult to navigate without the assistance of experienced counsel. Failure to comply with international trade rules and regulations—even if done so unwittingly—can lead to civil and criminal penalties, monitorships, consent agreements, debarment, reputational damage, substantial administrative burden, legal expense, and unsatisfied business objectives. Increasingly, there also is exposure for individual officers/directors, which can include monetary penalties and, potentially, jail time.
Experience 5 results
Experience
|March 31, 2023
Triumphed for Relevent Sports Before Second Circuit, Reviving Antitrust Suit Against FIFA, USSF
Experience
|February 28, 2023
Experience
|November 4, 2022
Atlis Motor Vehicles Announces Anticipated Initiation of Trading on NASDAQ Exchange
Winston & Strawn LLP represented Atlis Motor Vehicles, a vertically integrated startup electric vehicle technology ecosystem company developing an electric work truck and the batteries to power it, in connection with its application to list on the Nasdaq Exchange. Atlis anticipates initiation of trading on the Nasdaq Exchange on September 27, 2022. Atlis will be traded under the symbol “AMV.”
Insights & News 682 results
Client Alert
|May 1, 2025
|3 Min Read
April 2025 Executive Order Targets Prescription Drug Price Reduction
On April 15, 2025, President Trump signed an executive order titled “Lowering Drug Prices by Once Again Putting Americans First.” The subject matter of this executive order criss-crosses considerable policy ground in the overall U.S. pharmaceutical distribution chain. The executive order sets forth the administration’s statement of objectives to reduce prescription medication costs by promoting competition and eliminating practices that lead to high drug prices. Referencing regulatory and policy actions from the first Trump administration and the Biden administration’s policy steps, including the Inflation Reduction Act of 2022 aimed at lowering prescription drug prices for Medicare beneficiaries, the executive order sets forth a broad agenda to impact Medicare prescription drug costs, including in the Medicare Part D program.[1] The order directs the Secretary of Health and Human Services (HHS) to propose and seek comment on guidance for the Medicare Drug Price Negotiation Program and collaborate with Congress to align the treatment of small molecule drugs with biological products, citing concerns about industry investment distortions and cost increases for Medicare and its beneficiaries.[2]
Government Program Fraud, False Claims Act & Qui Tam Litigation Playbook
|May 1, 2025
|10+ Min Read
Future FCA Enforcement Expectations in Light of New Administration Priorities and 2024 Recoveries
The annual False Claims Act (FCA) recovery statistics issued by the U.S. Department of Justice for Fiscal Year 2024, coupled with the Trump administration’s focus on the elimination of waste, fraud, and abuse in government spending and apparent intentions to rely on the FCA to pursue other administration priorities, signal a likely increase in FCA investigations and actions throughout 2025 and beyond.
Competition Corner
|May 1, 2025
|2 Min Read
For companies operating in the U.S. consumer and retail space—whether in luxury goods, electronics, e-commerce, or mass retail—the current political and regulatory climate presents a shifting landscape of antitrust enforcement that’s worth watching closely.
Other Results 29 results
Site Content
What Is Anti-Bribery and Corruption?
The terms anti-bribery and anti-corruption encompass the laws, agreements, or policies aimed at stopping or punishing all forms of bribery and corruption. For example, under the Foreign Corrupt Practices Act (FCPA), it is unlawful for a U.S. person or company to offer, pay, or promise to pay money or anything of value to a foreign official for the purpose of corruptly obtaining or retaining business.
Site Content
What Is the Foreign Corrupt Practices Act (FCPA)?
The Foreign Corrupt Practices Act (FCPA) is a federal statute prohibiting United States citizens and entities from engaging in corruption. It has two main elements: (1) anti-bribery provisions, forbidding the giving or offering of anything of value to a foreign government official for business and (2) accounting requirements, establishing mandatory practice guidelines for companies to maintain accurate records and internal controls. The FCPA is enforced by the Department of Justice (DOJ) and the Securities and Exchange Commission (SEC).
Site Content
Anti-Money Laundering (AML) refers to policies and practices that prevent, detect, and report financial crimes. The principal U.S. federal law on money laundering is the Bank Secrecy Act (BSA), also known as the Currency and Foreign Transactions Reporting Act of 1970. The BSA generally mandates financial institutions to assist in governmental investigations by keeping records of cash purchases or negotiable instruments, filing reports of cash transactions exceeding a set daily aggregate amount, and reporting suspicious activity that may hint at money laundering, tax evasion, or other criminal activities.